Determining whether Assertio (ASRT) is a good stock to buy depends entirely on an investor's risk tolerance, portfolio strategy, and outlook on the specialty pharmaceutical sector. While bulls highlight portfolio diversification following recent oncology acquisitions and digital commercialization efficiencies, cautious analysts point to inherent industry risks, patent expirations, earnings volatility, and competitive pressures that require careful fundamental due diligence.